---
symbol: "MRNA"
name: "Moderna"
date: 2026-10-21
change_pct: 3.361099541857557
direction: "up"
event_type: "earnings"
url: "https://perplo.app/why/MRNA/2026-10-21"
updated_at: 2026-10-21T17:06:59.529Z
---

# Why Moderna (MRNA) rose 3.36% on October 21, 2026

Moderna (MRNA) rose 3.36% on October 21, 2026 — Phase 3 cancer vaccine readout nears, drawing buyers.

## What happened

Moderna rose 3.4% ahead of the release of Phase 3 trial results for its cancer vaccine. The data itself has not yet been reported.

## Why it moved

The cancer vaccine is a major part of Moderna's pipeline valuation, so investors buy ahead of the readout to position for a positive outcome. The move is a bet on the data, not a reaction to it.

## Why it matters

Moderna sits in the Healthcare & Biotech theme, where late-stage oncology readouts are the main catalysts for re-rating.

## What would break the thesis

Weak efficacy, a safety signal, or a missed endpoint would erase the pipeline premium and could send shares sharply lower.

## Sources

- [Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.](https://www.marketwatch.com/story/moderna-is-about-to-release-the-trial-results-for-its-cancer-vaccine-a-lot-is-riding-on-this-data-ccbf8c9c?mod=mw_rss_topstories) — MarketWatch
- [Moderna leads US momentum screen with gains of over 276% in three months](https://www.investing.com/news/stock-market-news/moderna-leads-us-momentum-screen-with-gains-of-over-276-in-three-months-93CH-4960566) — Investing.com

---

Trade MRNA perpetual futures 24/7 onchain: https://perplo.app/asset/MRNA